

*Vinodkumar Mugada¹, Vidyadhara Suryadevara², Manasa Cheekurumilli³,
Srinivasa Rao Yarguntla⁴*

**SIGNAL DETECTION IN PHARMACOVIGILANCE: METHODS, TOOLS,
AND WORKFLOWS FROM CASE IDENTIFICATION TO ADVERSE DRUG
REACTION DATABASE ENTRY**

¹Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Vignan Institute of Pharmaceutical Technology, Duvvada, AP, India

²Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Guntur, AP, India

³Department of Pharmacy Practice, Vignan Institute of Pharmaceutical Technology, Duvvada, AP, India

⁴Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Vignan Institute of Pharmaceutical Technology, Duvvada, AP, India

Received: 12.08.2025

Accepted for publication: 03.10.2025

Address for correspondence:

Vinodkumar Mugada
Department of Pharmacy Practice,
Faculty of Pharmaceutical Sciences,
Vignan Institute of Pharmaceutical Technology, Duvvada, AP, Visakhapatnam, India,
email: mugadavinodkumar18@vignanpharma.com

ABSTRACT

Adverse drug reactions (ADRs) remain a major, yet largely preventable, global public health challenge, causing significant morbidity, mortality, and healthcare costs. This review synthesises evidence on the global burden, pharmacovigilance systems, and prevention strategies for ADRs, integrating data from multiple regions, healthcare settings, and drug classes. Epidemiological findings reveal wide variability in incidence and mortality, with older adults, low-resource settings, and exposure to high-risk medicines – such as antibiotics, antiretrovirals, and cardiovascular agents – representing key vulnerabilities. Despite advances in surveillance, underreporting, data quality issues, and methodological biases persist, particularly in low- and middle-income countries. Comparative analyses of pharmacovigilance platforms, including World Health Organization's (WHO's) VigiBase, EudraVigilance, and EU-ADR, highlight complementary strengths and the value of integrating spontaneous reporting with electronic health record analytics. Emerging statistical methods, including machine learning and federated analytics, offer improved signal detection timeliness and precision. Prevention strategies span prescriber-level, system-level, and patient engagement interventions. These include clinical decision support systems, pharmacogenomic-guided therapy, deprescribing protocols, mobile reporting applications, and wearable biosensors. Evidence shows that active surveillance and automated alerts outperform voluntary reporting, while digital tools can enhance detection and risk communication. However, implementation remains uneven due to infrastructure, workforce, and policy gaps. Looking forward, achieving the World Health Organization's goal of halving severe medication-related harm by 2030 will require embedding ADR surveillance and prevention into universal health coverage frameworks. Policy priorities include mandating interoperable safety systems, harmonising international safety indicators, investing in capacity building for resource-limited settings, and aligning incentives with safer prescribing. Coordinated global action can bridge surveillance gaps, strengthen prevention, and build resilient, equitable pharmacovigilance systems, advancing both patient safety and sustainable health systems worldwide.

Keywords: *adverse drug reactions, pharmacovigilance, medication errors, patient safety, computer assisted signal detection*

STRESZCZENIE

Niepożądane działania leków (ADR) pozostają poważnym, choć w dużej mierze możliwym do uniknięcia, globalnym wyzwaniem dla zdrowia publicznego, generując znaczną zachorowalność, śmiertelność i koszty opieki zdrowotnej. Niniejszy przegląd syntetyzuje dowody dotyczące globalnego obciążenia, systemów nadzoru nad bezpieczeństwem farmakoterapii oraz strategii zapobiegania ADR, integrując dane z wielu regionów, placówek opieki zdrowotnej i klas leków. Wyniki epidemiologiczne ujawniają dużą zmienność zapadalności i śmiertelności, przy czym osoby starsze, placówki o niskich zasobach oraz osoby narażone na leki wysokiego ryzyka – takie jak antybiotyki, leki antyretrowirusowe i leki stosowane w chorobach układu krążenia – stanowią kluczowe obszary podatności. Pomimo postępów w nadzorze, nadal utrzymują się niedoszacowania, problemy z jakością danych i błędy metodologiczne, szczególnie w krajach o niskich i średnich dochodach. Analizy porównawcze platform nadzoru nad bezpieczeństwem farmakoterapii, w tym VigiBase, EudraVigilance i EU-ADR Światowej Organizacji Zdrowia (WHO), podkreślają uzupełniające się mocne strony i wartość integracji spontanicznego zgłaszania z analizą elektronicznej dokumentacji medycznej. Nowe metody statystyczne, w tym uczenie maszynowe i analityka federacyjna, oferują lepszą terminowość i precyzję wykrywania sygnałów. Strategie prewencyjne obejmują interwencje na poziomie lekarza przepisującego leki, systemu oraz zaangażowania pacjenta. Należą do nich systemy wspomagania decyzji klinicznych, terapia oparta na farmakogenomice, protokoły odstawiania leków, mobilne aplikacje raportujące oraz biosensory noszone na ciele. Dowody wskazują, że aktywny nadzór i automatyczne alerty przewyższają dobrowolne raportowanie, a narzędzia cyfrowe mogą usprawnić wykrywanie i komunikację dotyczącą ryzyka. Jednak wdrażanie pozostaje nierównomierne ze względu na luki w infrastrukturze, kadrze pracowniczej i polityce. W przyszłości osiągnięcie celu Światowej Organizacji Zdrowia, jakim jest zmniejszenie o połowę poważnych szkód związanych z lekami do 2030 roku, będzie wymagało włączenia nadzoru nad działaniami niepożądanymi leków i profilaktyki ADR do powszechnych ram opieki zdrowotnej. Priorytety polityczne obejmują wprowadzenie interoperacyjnych systemów bezpieczeństwa, harmonizację międzynarodowych wskaźników bezpieczeństwa, inwestowanie w budowanie potencjału w środowiskach o ograniczonych zasobach oraz dostosowanie zachęt do bezpieczniejszego przepisywania leków. Skoordynowane działania na skalę globalną mogą zniwelować luki w nadzorze, wzmocnić profilaktykę i zbudować odporne, sprawiedliwe

systemy nadzoru nad bezpieczeństwem farmakoterapii, zwiększając zarówno bezpieczeństwo pacjentów, jak i stabilność systemów opieki zdrowotnej na całym świecie.

Słowa kluczowe: *niepożądane działania leków, nadzór farmaceutyczny, błędy w stosowaniu leków, bezpieczeństwo pacjenta, komputerowe wspomaganie wykrywania sygnałów*

INTRODUCTION

Adverse drug reactions (ADRs) are harmful and unintended responses to medications administered at normal therapeutic doses and are a significant concern in both clinical practice and public health. The World Health Organization defines an ADR as "a response to a medicine which is noxious and unintended, and which occurs at doses normally used in man" (1). The European Union broadens this definition to include reactions arising from medication errors, misuse, or off-label use, thereby expanding the remit of pharmacovigilance (2). On the other hand, an adverse event is "Any untoward medical occurrence in a subject to whom a medicinal product is administered and which does not necessarily have a causal relationship with this treatment" (3). ADRs account for approximately 6% of hospital admissions, rank among the top six causes of mortality in high-income countries, and contribute to over 100,000 deaths annually in the United States (4). The Global Burden of Disease Study reports a decline in the disability-adjusted life year (DALY) rate attributable to ADRs, from 84.93 to 62.79 per 100,000 between 1990 and 2017, yet substantial regional disparities remain (5). Compared to healthcare-associated infections (HCAIs), up to 87.1% of ADRs in hospitalized patients are preventable (6,7), and this highlights ADRs as a preventable global public health threat (8). In response, the World Health Organization launched the Medication Without Harm initiative to achieve a 50% reduction in severe medication-related harm by 2027. This objective aligns with Sustainable Development Goal (SDG) 3.8, which promotes universal access to safe, effective, and affordable medicines, and SDG 3.b addresses treatment gaps through improved medication safety practices (9,10).

The current review aimed to quantify the global impact of ADRs by assessing incidence, mortality, and DALY metrics and by identifying vulnerable populations and high-risk drug classes (11,12), to evaluate pharmacovigilance systems, including WHO's VigiBase and the EU-ADR network, as essential mechanisms for early safety signal detection and validation (13,14), and to examine how validated safety signals inform targeted interventions, such as

prescriber decision-support tools, deprescribing protocols, and public engagement strategies, to mitigate harm at both clinical and population levels (10,15).

EPIDEMIOLOGY OF ADRs

FACTORS INFLUENCING INCIDENCE OF ADRs

Multiple factors influence the incidence of ADRs. Studies report several factors that influence the occurrence of ADRs including: older age, female gender, higher number of co-morbidities, increased number of drugs, receiving potentially inappropriate medication (PIM), use of herbal remedy in previous 4 weeks, renal diseases, hepatic conditions, and previous ADRs (16-24).

GLOBAL BURDEN

The incidence and mortality rates of ADRs vary markedly across healthcare settings due to differences in pharmacovigilance capacity, drug utilisation patterns, and population characteristics. Prospective hospital-based studies illustrate this heterogeneity: in Ethiopia, the incidence was 27.4 ADRs per 100 admissions (95% CI: 19.8–30.4); in Uganda, 48.9% of elderly inpatients experienced at least one ADR, corresponding to 78 ADRs per 1000 person-days; in Korea, prevalence reached 10.2%; and in Italian medical wards, 3.2% (7, 25-27).

Older adults are consistently at higher risk. In the Ugandan cohort, nearly half of patients experienced an ADR during six months of follow-up, echoing findings from a seminal U.S. meta-analysis estimating an overall ADR incidence of 6.7% and fatal ADRs at 0.32% (25,28). Mortality data further highlight this impact: in South African medical wards, ADRs contributed to 2.9% of all deaths and 16% of in-hospital mortality (29). A recent meta-analysis confirmed a significant association between suspected ADRs and mortality (OR: 1.50; 95% CI: 1.21–1.86) (30).

Consistent patterns emerge across regions. In Ethiopia, antibiotics accounted for 26.2% of ADRs, followed by cardiovascular medicines at 24.7% (25). South African reports implicated antiretrovirals (notably tenofovir), anti-tuberculosis drugs (e.g., rifampicin), and cotrimoxazole as leading causes of fatal ADRs (31). In Korea, opioids were most frequently associated overall, while antibiotics dominated serious ADR categories (27). In Eritrea, 64% of patients receiving combination ART required regimen changes – incidence 12.3 per 1000 person-months – most often due to toxicity, treatment failure, or shortages (32). Despite widespread NSAID use in Southeast Asia, region-specific evidence linking these agents to renal injury or hospitalisation is limited, representing a notable surveillance gap.

REGIONAL AND HIGH-RISK PATTERNS

In Europe, ADR-related hospitalisations are disproportionately common among older adults. A large-scale review reported that 3.5% of admissions in those ≥ 65 years were ADR-related, with 10.1% experiencing an ADR during hospitalisation (33). The Irish ADAPT study found a 10.0% incidence of ADR-related admissions (95% CI: 9.1%–11.0%), 71.1% of which were potentially preventable (34). A broader review estimated a pooled prevalence of 11.0% (95% CI: 5.1%–16.8%), with individual cohorts reporting rates as high as 46.3% (35). A meta-analysis estimated ADR-related hospitalisation at 8.3% (95% CI: 6.4%–10.7%) in elderly populations (36). Sex-based differences are also evident. Italian pharmacovigilance data from over 300,000 reports showed higher overall ADR reporting in women (55.6% vs. 43.1%), but greater ADR-related mortality in men (37). In Sweden, women reported more ADRs (57% vs. 42%), yet severe ADRs were more frequent in men after adjustment (37).

DATA GAPS AND BIASES IN GLOBAL ADR SURVEILLANCE

Capture-recapture analyses consistently highlight substantial underreporting in hospital pharmacovigilance. The median underreporting rate in Iran was 76.0% (IQR: 64.32–81.35) (38). In France, notification rates for drug-induced acute kidney injury were as low as 6.1%, suggesting approximately 94% of events go unreported (39); another French study found rates of 12.9% (95% CI: 10.0–15.8) for similar outcomes (40). Low- and middle-income countries face recurring challenges, including low reporting rates, fragmented national systems, poor coordination, and reliance on short-term educational interventions (41). Additional barriers such as limited infrastructure, language constraints, stigma, and workforce shortages are reported across Africa and Southeast Asia (42). Studies in India reveal a gap between theoretical pharmacovigilance knowledge and reporting behaviours (43–46). In Rwanda, targeted education programmes improved ADR awareness and reporting (47).


Estimating true ADR incidence is complicated by unreliable denominators in spontaneous reporting systems, introducing bias into prevalence and risk calculations. A systematic review of signal detection algorithms reaffirmed these methodological limitations (48). Multi-source capture–recapture methods address under-ascertainment and confirm that no single source, such as spontaneous reports or administrative databases, offers complete coverage (39,40,49). Triangulation remains essential for accurate epidemiological estimates.

PHARMACOVIGILANCE AND SIGNAL DETECTION

VigiBase, the WHO global repository for post-marketing surveillance, collects ADR reports on medicines and vaccines from national pharmacovigilance centres across member states of the WHO Programme for International Drug Monitoring (50). Submitted reports undergo standardised processing before integration (51). The database encompasses data from 36 countries, with region-specific analyses such as those involving the UN Asia region between 2016 and 2021 (52,53). Continuous updates and rigorous quality checks maintain harmonisation across reporting centres (51).

EudraVigilance serves as the pharmacovigilance infrastructure for the European Economic Area, capturing suspected ADRs for all authorised medicines (54). It records both serious and non-serious ADRs from marketing authorisation onwards. Examples include opioid safety analyses in Germany and longitudinal fosfomycin safety surveillance from initial approval to October 2021 (55,56).

The EU-ADR Web Platform links longitudinal EHR data from multiple European nations, using distributed analytics to identify drug-event associations (57). Integration of clinical datasets enables scalable, near-real-time signal detection that complements spontaneous reporting systems. Studies show that integrating spontaneous reporting systems with EHR-based databases can improve detection timeliness and accuracy. Cost-effectiveness analyses recommend tailoring system selection to the event type and data resource availability (58).



HCP – Healthcare Professional; MAH – Marketing Authorisation Holder; NPC – National Pharmacovigilance Centre; MedDRA – Medical Dictionary for Regulatory Activities; IC/PRR/ROR – Information Component /Proportional Reporting Ratio/Reporting Odds Ratio; SmPC – Summary of Product Characteristics; RMP – Risk-Minimisation Plan.

Figure 1. Signal detection and evaluation process in pharmacovigilance. Spontaneous reports from patients, HCPs, and MAH are verified by the NPC and forwarded to VigiBase/EudraVigilance for standardisation and quality control; statistical screening and clinical evaluation inform regulatory actions (SmPC updates, RMP) and safety communications.

DATA QUALITY AND PREPROCESSING

The **VigiMatch algorithm** applies probabilistic matching to identify likely duplicate records by rewarding matched fields and penalising discrepancies (59,60). Validation studies report positive predictive values from 86% in the UK to 33% in Spain, with most false positives representing related rather than unrelated cases (60). VigiMatch has detected duplicates overlooked by rule-based systems. However, 2025 evaluations show newer models outperform VigiMatch across precision, recall, and false positive rates (61).

Accurate denominator estimation is essential for metrics such as the Proportional Reporting Ratio (PRR). The ATC/DDD (Anatomical Therapeutic Chemical /Defined Daily Dose) methodology standardises usage rates by calculating drug consumption per 1000 inhabitants per day, incorporating prescription volume (N), dose (M), pack size (Q), the assigned WHO DDD, population (P), and time period (T) (62,63). This harmonised approach corrects for variations in prescribing patterns and enables cross-country comparability.

CORE STATISTICAL ENGINES

Signal detection relies on robust statistical methodologies. Traditional disproportionality measures – Information Component (IC), PRR, and Reporting Odds Ratio (ROR) – remain widely used, while machine learning techniques increasingly supplement or replace them, offering improved sensitivity, specificity, and timeliness. In an analysis of immune checkpoint inhibitor-related ADRs in paediatric oncology using VigiBase and Food and Drug Administration Adverse Drug Event Reporting System (FAERS), IC achieved the highest sensitivity (100%), followed by ROR (60%) and PRR (40%) (64). ROR demonstrated superior timeliness, detecting signals approximately one quarter earlier than PRR and IC (65,66). Gradient Boosting Machines (GBM) have achieved higher sensitivity (79%) and specificity (79%) than ROR (18%) and IC (21%) (67). Hybrid frameworks combining pharmacological network modelling with Bayesian algorithms have further improved performance, with an AUC of 0.8291 versus IC (0.7343), ROR (0.6828), and PRR (0.6721) (68).

PERFORMANCE AND IMPACT

Analysis of 4,520 safety signals in VigiBase revealed a median time to communication (TTC) of 9 years from first report to regulatory action (69). This delay was consistent for both designated medical events (DMEs) and other signals, with intermediate timelines showing 7 years from the accumulation of three cases and 6 years from disproportionality detection to communication. Over time, TTC has lengthened – rising from 5 to 9 years for DMEs and from 4 to 10 years for non-DMEs (59). Evidence on the positive predictive value (PPV) of VigiBase signals validated by regulators between 2015 and 2024 is limited, with most research focusing on cross-database signal consistency rather than downstream clinical or regulatory outcomes (70).

EMERGING INNOVATIONS: FEDERATED ANALYTICS FOR DISTRIBUTED SURVEILLANCE

The Sentinel System enables participating institutions to execute standardised queries locally, sharing anonymised aggregate data for central analysis (71). This model accelerates processing while maintaining data privacy. The Observational Health Data Science and Informatics (OHDSI) initiative advances global collaboration by developing open-source tools and a Common Evidence Model for real-world data analytics complementing the traditional and EHR-based systems described earlier (72).

PREVENTION AND MITIGATION STRATEGIES PRESCRIBER-LEVEL INTERVENTIONS

In the AF-ALERT randomized controlled trial of 458 hospitalized atrial fibrillation patients, alert-based CDSS significantly increased anticoagulation prescription rates (25.8% vs. 9.5%, $P < 0.0001$) and reduced composite adverse outcomes at 90 days (11.3% vs. 21.9%, $P = 0.002$) (73). The CODES pragmatic trials in Italian hospitals, involving over 10,000 patients, demonstrated progressive acceptance of EBMEDS-MediDSS as a reliable clinical tool (74).

The OPERAM multicenter trial applied CDSS-assisted STOPP/START criteria in 819 older inpatients with polypharmacy, generating 5,080 medication-related signals with 39% acceptance by pharmacotherapy teams (75). Large multicenter trials such as SENATOR and OPERAM, however, did not show significant reductions in ADRs, mortality, or drug-related readmissions, contrasting with positive single-center results (76). A meta-analysis of eight randomized controlled trials ($n = 6,708$) found that CYP2C19 genotype-guided antiplatelet therapy reduced major adverse cardiovascular events (RR 0.71, 95% CI 0.51–0.98, $p = 0.04$)

and myocardial infarction risk (RR 0.56, 95% CI 0.40–0.78, $p < 0.01$) without increasing bleeding risk (77). CYP2C19 loss-of-function carriers on clopidogrel had a 62% higher MACE risk than those on alternative P2Y12 antagonists (RR 1.62, 95% CI 1.42–1.86, $p < 0.00001$), with pronounced effects in Asian populations (78).

SYSTEM-LEVEL APPROACHES

WHO’s “Medication Without Harm” challenge has been implemented using varied strategies, though measurable reductions in harm remain sparsely documented. In one evaluation, 83% of participants rated the “Five Moments for Medication Safety” materials as useful (79). Active surveillance methods consistently outperform voluntary reporting in ADR detection. In Ahmedabad, a Preliminary Trigger Tool List identified 66 ADRs in 327 patients (PPV 19.27%, sensitivity 100%, specificity 21.66%); its modified version detected 23 ADRs compared to 16 via spontaneous reporting, capturing more moderately severe and preventable cases (80). In oncology, the Global Trigger Tool identified 0.90 adverse events per patient compared to 0.24 via voluntary reporting, with only 2% overlap between the two methods (81).

Electronic health record–embedded alerts have achieved significant prescribing improvements. DOAC alerts prompted prescription modification in 34.2% of inappropriate cases (82). Surgical opioid alerts reduced inappropriate prescribing from 48% to 3% and lowered mean opioid supply from 92 to 57 oral morphine milligram equivalents (Rizk et al., 2024). Acute kidney injury alerts improved physician awareness, increasing creatinine follow-up rates (56.6% to 65.8%) and nephrotoxic drug discontinuation (59.2% to 63.2%) (83).

PATIENT & PUBLIC ENGAGEMENT

The Med Safety mobile application, adapted for eight national pharmacovigilance systems, has enhanced ADR reporting capacity (84). Post-implementation surveys indicated increased case safety reports and positive user experiences, though active reporting remained limited in some contexts. In Ghana, 64.7% of healthcare professionals continued using the app post-installation, yet only 27.3% submitted ADR reports (85). In Uganda, strong acceptability was reported, with offline functionality and two-way risk communication cited as facilitators; training significantly improved adoption rates (86). An app-based reporting can strengthen communication between national pharmacovigilance centres and healthcare professionals, with potential to enhance signal detection (85,86).

FUTURE PRIORITIES

Pilot studies highlight the potential of wearable biosensors for early detection of drug-induced complications. QTNet, a deep learning model, detected dofetilide-induced QT prolongation with 87% sensitivity and 77% specificity using single-lead ECG from wearable devices (87). The BodyGuardian™ system reliably measured QT intervals with <15 ms disagreement compared to manual assessment (88). For hypoglycaemia, the VitalConnect HealthPatch MD identified 28 of 39 events via heart rate variability changes (89), and smartwatch-based monitoring achieved an AUC of 0.76 ± 0.07 using multiple physiological indicators (90).

Digital twin models offer personalised dosing by integrating individual physiological and clinical parameters. For example, a fentanyl protocol in advanced cancer optimised transdermal delivery and reduced ADR risk (91). Structured implementation frameworks can enhance deprescribing. Focus groups with 54 geriatricians and pharmacists identified five priority domains for hospital-based interventions, yielding 44 evidence-based components (91). In Swiss nursing homes, interprofessional quality circles supported deprescribing but were difficult to sustain after trial completion (92).

CONCLUSION

Adverse drug reactions remain a preventable global burden. Pharmacovigilance approaches, namely spontaneous reporting, EHR surveillance, and federated analytics, are complementary but constrained by under-reporting, uneven data quality, and delayed validation. Machine-learning advances improve detection; preventive strategies such as clinical decision support, pharmacogenomics, and deprescribing, show impact yet face uneven implementation. Embedding medication safety in universal coverage, enabling interoperable data sharing, and building capacity, especially in LMICs, are essential to sustainably reduce ADR-related morbidity and mortality.

- Embed medication safety in universal coverage and national patient-safety agendas
- Mandate interoperable pharmacovigilance, real-time data sharing, and streamlined reporting systems
- Prioritize LMIC capacity building and adoption of preventive genomic-guided interventions

REFERENCES

1. World Health Organization. Safety of Medicines A guide to detecting and reporting adverse drug reactions [Internet]. Available from: https://apps.who.int/iris/bitstream/handle/10665/67378/WHO_EDM_QSM_2002.2.pdf [access: 02.08.2025].
2. Fornasier G, Francescon S, Leone R, Baldo P. An historical overview over Pharmacovigilance. *Int J Clin Pharm*. 2018;40:744-47. doi.org/10.1007/s11096-018-0657-1.
3. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Annex I -Definitions (Rev 5) Date for coming into effect of Revision 5, 2024. 2024. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-annex-i-definitions-rev-5_en.pdf
4. Le Louët H, Pitts PJ. Twenty-First Century Global ADR Management: A Need for Clarification, Redesign, and Coordinated Action. *Ther Innov Regul Sci*. 2023;57:100–03. <http://dx.doi.org/10.1007/s43441-022-00443-8>.
5. Khan Z, Karatas Y, Akici A, Martins MAP, Ahmad N. Editorial: Pharmacoepidemiology and pharmacovigilance post-marketing drug safety studies. *Front Pharmacol*. 2024;15:1473052. <http://dx.doi.org/10.3389/fphar.2024.1473052>.
6. Hakkarainen KM, Hedna K, Petzold M, Hägg S. Percentage of Patients with Preventable Adverse Drug Reactions and Preventability of Adverse Drug Reactions – A Meta-Analysis. *PLoS One*. 2012;7(3):e33236.doi.org/10.1371/journal.pone.0033236
7. Giardina C, Cutroneo PM, Mocciaro E, Russo GT, Mandraffino G, Basile G, et al. Adverse Drug Reactions in Hospitalized Patients: Results of the FORWARD (Facilitation of Reporting in Hospital Ward) Study. *Front Pharmacol*. 2018;9:350. <http://dx.doi.org/10.3389/fphar.2018.00350>.
8. Razzaque MS. Healthcare-associated infections in the context of the pandemic. *Front Health Serv*. 2023;3:1288033. <http://dx.doi.org/10.3389/frhs.2023.1288033>.
9. Chattu VK, Singh B, Pattanshetty S, Reddy KS. Access to medicines through global health diplomacy. *Health Promot Perspect*. 2023;13:40–46. <http://dx.doi.org/10.34172/hpp.2023.05>.

10. World Health Organization (WHO). Medication without harm. Available from: <https://www.who.int/initiatives/medication-without-harm> [access: 22.10.2024].
11. Kamath A, Acharya SD, Bharathi RP. Burden of death and disability due to adverse effects of medical treatment in India: An analysis using the global burden of disease 2019 study data. *Heliyon*. 2024;10:e24924.doi.org/10.1016/j.heliyon.2024.e24924.
12. Kommu S, Carter C, Whitfield P. Adverse Drug Reactions. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK599521> [access: 02.08.2025].
13. Uppsala Monitoring Centre. VigiBase: WHO's global database signalling harm and pointing to safer use. Available from: <https://who-umc.org/vigibase/vigibase-who-s-global-database> [access: 02.08.2025].
14. Trifiro G, Fourrier-Reglat A, Sturkenboom MCJM, Díaz Acedo C, Van Der Lei J, EU-ADR Group. The EU-ADR project: preliminary results and perspective. *Stud Health Technol Inform*. 2009;148:43–49. Available from: <https://pubmed.ncbi.nlm.nih.gov/19745234/>.
15. Al-Zadjali B, Al-Busaidi B. Medications Without Harm? *Oman Med J*. 2018;33:451–52. <http://dx.doi.org/10.5001/omj.2018.84>.
16. Sneha SG, Simhadri K, Subeesh VK, Sneha SV. Predictors of adverse drug reactions in geriatric patients: An exploratory study among cancer patients. *South Asian J Cancer*. 2019 Apr-Jun;8(2):130-133. doi: 10.4103/sajc.sajc_218_18.
17. Alhawassi TM, Krass I, Bajorek BV, Pont LG. A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting. *Clin Interv Aging*. 2014 Dec 1;9:2079-86. doi: 10.2147/CIA.S71178.
18. O'Mahony D, O'Connor MN, Eustace J, Byrne S, Petrovic M, Gallagher P. The adverse drug reaction risk in older persons (ADRROP) prediction scale: derivation and prospective validation of an ADR risk assessment tool in older multi-morbid patients. *Eur Geriatr Med*. 2018 Apr;9(2):191-199. doi: 10.1007/s41999-018-0030-x.
19. Veloso RC de SG, Figueredo TP de, Barroso SCC, Nascimento MMG do, Reis AMM, Veloso RC de SG, et al. Fatores associados às interações medicamentosas em idosos internados em hospital de alta complexidade. *Ciência & Saúde Coletiva*. 2019;24(1):17–26. https://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-81232019000100017&lng=pt&nrm=iso&tlng=pt

20. O'Connor MN, Gallagher P, Byrne S, O'Mahony D. Adverse drug reactions in older patients during hospitalisation: are they predictable? *Age Ageing*. 2012 Nov;41(6):771-6. doi: 10.1093/ageing/afs046.
21. Kiguba R, Karamagi C, Bird SM. Incidence, risk factors and risk prediction of hospital-acquired suspected adverse drug reactions: a prospective cohort of Ugandan inpatients. *BMJ Open*. 2017 Jan 20;7(1):e010568. doi: 10.1136/bmjopen-2015-010568.
22. Leendertse AJ, Egberts AC, Stoker LJ, van den Bemt PM; HARM Study Group. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. *Arch Intern Med*. 2008 Sep 22;168(17):1890-6. doi: 10.1001/archinternmed.2008.3.
23. Onder G, Petrovic M, Tangiisuran B, Meinardi MC, Markito-Notenboom WP, Somers A, et al. Development and Validation of a Score to Assess Risk of Adverse Drug Reactions Among In-Hospital Patients 65 Years or Older. *Archives of Internal Medicine*. 2010 Jul 12;170(13).
24. Zopf Y, Rabe C, Neubert A, Hahn EG, Dormann H. Risk factors associated with adverse drug reactions following hospital admission: a prospective analysis of 907 patients in two German university hospitals. *Drug Saf*. 2008;31(9):789-98. doi: 10.2165/00002018-200831090-00007.
25. Sendekie AK, Netere AK, Tesfaye S, Dagne EM, Belachew EA. Incidence and patterns of adverse drug reactions among adult patients hospitalized in the University of Gondar comprehensive specialized hospital: A prospective observational follow-up study. *PLoS One*. 2023;18:e0282096. <http://dx.doi.org/10.1371/journal.pone.0282096>.
26. Yadesa TM, Kitutu FE, Tamukong R, Alele PE. Prevalence, Incidence, and Characteristics of Adverse Drug Reactions Among Older Adults Hospitalized at Mbarara Regional Referral Hospital, Uganda: A Prospective Cohort Study. *Clin Interv Aging*. 2021;16:1705–21. <http://dx.doi.org/10.2147/CIA.S332251>.
27. Seo B, Yang M-S, Park S-Y, Park BY, Kim J-H, Song WJ, et al. Incidence and Economic Burden of Adverse Drug Reactions in Hospitalization: A Prospective Study in Korea. *J Korean Med Sci*. 2023;38:e56. <http://dx.doi.org/10.3346/jkms.2023.38.e56>.
28. Lazarou J, Pomeranz BH, Corey PN. Incidence of Adverse Drug Reactions in Hospitalized Patients. *JAMA*. 1998;279:1200–05. doi: 10.1001/jama.279.15.1200.
29. Mouton JP, Mehta U, Parrish AG, Wilson DPK, Stewart A, Njuguna CW, et al. Mortality from adverse drug reactions in adult medical inpatients at four hospitals in

- South Africa: a cross-sectional survey. *Br J Clin Pharmacol*. 2015;80:818–26. <http://dx.doi.org/10.1111/bcp.12567>.
30. Patel TK, Patel PB, Bhalla HL, Dwivedi P, Bajpai V, Kishore S. Impact of suspected adverse drug reactions on mortality and length of hospital stay in the hospitalised patients: a meta-analysis. *Eur J Clin Pharmacol*. 2023;79:99–116. <http://dx.doi.org/10.1007/s00228-022-03419-7>.
 31. Mouton JP, Mehta U, Parrish AG, Wilson DPK, Stewart A, Njuguna CW, et al. Mortality from adverse drug reactions in adult medical inpatients at four hospitals in South Africa: a cross-sectional survey. *Br J Clin Pharmacol*. 2015;80:818–26. <http://dx.doi.org/10.1111/bcp.12567>.
 32. Mengistu ST, Yohannes A, Issaias H, Mesfn M, Zerufael S, Dirar A, et al. Antiretroviral therapy regimen modification rates and associated factors in a cohort of HIV/AIDS patients in Asmara, Eritrea: a 16-year retrospective analysis. *Sci Rep*. 2023;13:14122. <http://dx.doi.org/10.1038/s41598-023-30804-8>.
 33. Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of Adverse Drug Reactions in Europe: A Review of Recent Observational Studies. *Drug Saf*. 2015;38:437–53. <http://dx.doi.org/10.1007/s40264-015-0281-0>.
 34. Cahir C, Curran C, Walsh C, Hickey A, Brannigan R, Kirke C, et al. Adverse drug reactions in an ageing PopulaTion (ADAPT) study: Prevalence and risk factors associated with adverse drug reaction-related hospital admissions in older patients. *Front Pharmacol*. 2023;13:1029067. <http://dx.doi.org/10.3389/fphar.2022.1029067>
 35. Pont L, Alhawassi T, Bajorek B, Krass I. A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting. *Clin Interv Aging*. 2014;9:2079–86. <http://dx.doi.org/10.2147/CIA.S71178>
 36. Haerdtlein A, Debold E, Rottenkolber M, Boehmer AM, Pudritz YM, Shahid F, et al. Which Adverse Events and Which Drugs Are Implicated in Drug-Related Hospital Admissions? A Systematic Review and Meta-Analysis. *J Clin Med*. 2023;12:1320. <http://dx.doi.org/10.3390/jcm12041320>.
 37. Brabete AC, Greaves L, Maximos M, Huber E, Li A, Lê M-L. A Sex- and Gender-Based Analysis of Adverse Drug Reactions: A Scoping Review of Pharmacovigilance Databases. *Pharmaceuticals*. 2022;15:298. <http://dx.doi.org/10.3390/ph15030298>
 38. Khalili M, Mesgarpour B, Sharifi H, Golozar A, Haghdooost AA. Estimation of Adverse Drug Reaction Reporting in Iran: Correction for Underreporting. *Pharmacoepidemiol Drug Saf*. 2021;30:1654–62. <http://dx.doi.org/10.1002/pds.5235>.

39. Rey A, Gras V, Moragny J, Choukroun G, Masmoudi K, Liabeuf S. Use of the Capture-Recapture Method to Estimate the Frequency of Community- and Hospital-Acquired Drug-Induced Acute Kidney Injuries in French Databases. *Front Pharmacol.* 2022;13:899164. <http://dx.doi.org/10.3389/fphar.2022.899164>.
40. Rolland A-L, Garnier A, Meunier K, Drablier G, Briet M. Drug-Induced Acute Kidney Injury: A Study from the French Medical Administrative and the French National Pharmacovigilance Databases Using Capture-Recapture Method. *J Clin Med.* 2021;10:168. <http://dx.doi.org/10.3390/jcm10020168>.
41. Menang O, Kuemmerle A, Maigetter K, Burri C. Strategies and interventions to strengthen pharmacovigilance systems in low-income and middle-income countries: a scoping review. *BMJ Open.* 2023;13:e071079. <http://dx.doi.org/10.1136/bmjopen-2022-071079>.
42. Sree Sudha TY, Meena B, Pareek S, Singh H. Enhancing pharmacovigilance for robust drug safety monitoring: addressing underreporting and collaborative solutions. *Ther Adv Drug Saf.* 2024;15:20420986241285927. doi.org/10.1177/20420986241285927.
43. Anusha S, Srinath S, Kavya M. A Study of Knowledge, Attitude, and Practice of Pharmacovigilance Among II-Year Undergraduate Medical Students and Interns at a Tertiary Care Teaching Hospital. *Asian J Pharm Clin Res.* 2024;17:97–102. <http://dx.doi.org/10.22159/ajpcr.2024v17i9.51240>.
44. Doshi N, Prajapati B, Selvaraj L. A Pharmacovigilance Study on Adverse Drug Reaction Profile at a Tertiary Care Teaching Hospital from Western Part of India. *Int J Pharm Investig.* 2025;15:562–72. <http://dx.doi.org/10.5530/ijpi.20250144>
45. Rushitaben KB, Goswami N, Shah S. Evaluation of Knowledge, Attitude, And Practice About Pharmacovigilance Among Nursing Staff at Tertiary Care Teaching Hospital. *Asian J Pharm Clin Res.* 2024;17:136–39. <http://dx.doi.org/10.22159/ajpcr.2024v17i11.52264>.
46. Raikar SR, Sneha S, G S, R J. Awareness and Knowledge of Adverse Drug Reactions and Pharmacovigilance Among Medical and Nursing Students and Staff in a Tertiary Care Hospital. *Cureus.* 2024;16:e69981. <http://dx.doi.org/10.7759/cureus.69981>.
47. Gashumba OU, Munyaneza E, Twahirwa S, Nzamukosha A, Musengamana V, Ryamukuru D. Impact of educational interventions on knowledge, attitude, practice toward pharmacovigilance and adverse drug reaction reporting among healthcare professionals at the University Teaching Hospital, Rwanda. *Rwanda Med J.* 2024;81:9–19. <http://dx.doi.org/10.4314/rmj.v81i2.7>.

48. Jiao X-F, Pu L, Lan S, Li H, Zeng L, Wang H, et al. Adverse drug reaction signal detection methods in spontaneous reporting system: A systematic review. *Pharmacoepidemiol Drug Saf.* 2024;33:e5768. <http://dx.doi.org/10.1002/pds.5768>.
49. Lugardon S, Desboeuf K, Fernet P, Montastruc J-L, Lapeyre-Mestre M. Using a capture–recapture method to assess the frequency of adverse drug reactions in a French university hospital. *Br J Clin Pharmacol.* 2006;62:225–32. <http://dx.doi.org/10.1111/j.1365-2125.2006.02633.x>.
50. De C, Sanz EJ, Leon J. Pharmacovigilance in Action: Utilizing Vigibase Data to Improve Clozapine Safety. *Patient Prefer Adherence.* 2024;18:2261–80. <http://dx.doi.org/10.2147/ppa.s495254>.
51. Bui T-V, Prot-Bertoye C, Ayari H, Baron S, Bertocchio J-P, Bureau C, et al. Safety of Inulin and Sinistrin: Combining Several Sources for Pharmacovigilance Purposes. *Front Pharmacol.* 2021;12:725417. <http://dx.doi.org/10.3389/fphar.2021.725417>.
52. Bahta M, Russom N, Ghebrenegus AS, Okubamichael YT, Russom M. Omeprazole and Risk of Hypertension: Analysis of Existing Literature and the WHO Global Pharmacovigilance Database. *Drugs Real World Outcomes.* 2024;11:241–51. <http://dx.doi.org/10.1007/s40801-024-00441-2>.
53. Barvaliya MJ, Chetan AC, Chandan N, Ray SK, Hegde HV, Unger BS, et al. Suspected cutaneous adverse drug reactions reported with traditional medicines: analysis of data for United Nations Asia region from WHO Vigibase. *Front Pharmacol.* 2023;14:1088841. doi.org/10.3389/fphar.2023.1088841.
54. Postigo R, Brosch S, Slattery J, van Haren A, Dogné J-M, Kurz X, et al. EudraVigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health Protection. *Drug Saf.* 2018;41:665–75. doi.org/10.1007/s40264-018-0647-1.
55. Jobski K, Bantel C, Hoffmann F. Characteristics and completeness of spontaneous reports by reporter's role in Germany: An analysis of the EudraVigilance database using the example of opioid-associated abuse, dependence, or withdrawal. *Pharmacol Res Perspect.* 2023;11(2):e1077. <http://dx.doi.org/10.1002/prp2.1077>.
56. Scavone C, Mascolo A, Bernardi FF, Aiezza ML, Saturnino P, Morra G, et al. Hyponatremia During Intravenous Treatment With Fosfomycin: A Retrospective Medical Record Review Study and an Analysis of Spontaneous Reports in the EudraVigilance Database. *Front Pharmacol.* 2022;13:844122. <http://dx.doi.org/10.3389/fphar.2022.844122>.

57. Oliveira JL, Lopes P, Nunes T, Campos D, Boyer S, Ahlberg E, et al. The EU-ADR Web Platform: delivering advanced pharmacovigilance tools. *Pharmacoepidemiol Drug Saf.* 2012;22:459–67. <http://dx.doi.org/10.1002/pds.3375>.
58. Pacurariu AC, Straus SM, Trifirò G, Schuemie MJ, Gini R, Herings R, et al. Useful Interplay Between Spontaneous ADR Reports and Electronic Healthcare Records in Signal Detection. *Drug Saf.* 2015;38:1201–10. <http://dx.doi.org/10.1007/s40264-015-0341-5>.
59. World Health Organization. Uppsala Monitoring Centre. *vigiMethods*. Available from: <https://who-umc.org/research/vigimethods/> [access: 02.08.2025].
60. Tregunno PM, Fink DB, Fernandez-Fernandez, Lázaro-Bengoia E, Norén GN. Performance of Probabilistic Method to Detect Duplicate Individual Case Safety Reports. *Drug Saf.* 2014;37:249–58. <http://dx.doi.org/10.1007/s40264-014-0146-y>.
61. Barrett JW, Erlanson N, China JF, Niklas NG. A Scalable Predictive Modelling Approach to Identifying Duplicate Adverse Event Reports for Drugs and Vaccines. *arXiv [Preprint]*. 2025. Available from: <https://arxiv.org/abs/2504.03729>.
62. World Health Organization (WHO). ATC/DDD for Drug Safety Assessment. Available from: <https://www.who.int/tools/atc-ddd-toolkit/dsa> [access: 02.08.2025].
63. Hollingworth S, Kairuz T. Measuring Medicine Use: Applying ATC/DDD Methodology to Real-World Data. *Pharmacy (Basel)*. 2021;9(1):60. <http://dx.doi.org/10.3390/pharmacy9010060>.
64. Shen J, Lin A, Cheng Q, Zhang J, Luo P. Abstract 6380: Exploring immune checkpoint inhibitor-related adverse events in pediatric cancer patients: A pharmacovigilance analysis of *VigiBase* and the FDA adverse event reporting system (FAERS) database. *Cancer Res.* 2024;84(6_Suppl):6380. <http://dx.doi.org/10.1158/1538-7445.AM2024-6380>.
65. Subeesh V, Maheswari E, Saraswathy GR, Swaroop AM, Minnikanti SS. A Comparative Study of Data Mining Algorithms used for Signal Detection in FDA AERS Database. *J Young Pharm.* 2018;10:444–49. <http://dx.doi.org/10.5530/jyp.2018.10.97>.
66. Chen Y, Guo JJ, Steinbuch M, Lin X, Buncher CR, Patel NC. Comparison of Sensitivity and Timing of Early Signal Detection of Four Frequently Used Signal Detection Methods. *Pharm Med.* 2008;22:359–65. <http://dx.doi.org/10.1007/bf03256733>.

67. Lee J-E, Kim JH, Bae J-H, Song I, Shin J-Y. Detecting early safety signals of infliximab using machine learning algorithms in the Korea adverse event reporting system. *Sci Rep.* 2022;12:14914. <http://dx.doi.org/10.1038/s41598-022-18522-z>.
68. Ji X, Cui G, Xu C, Hou J, Zhang Y, Ren Y. Combining a Pharmacological Network Model with a Bayesian Signal Detection Algorithm to Improve the Detection of Adverse Drug Events. *Front Pharmacol.* 2022;12:773135. <http://dx.doi.org/10.3389/fphar.2021.773135>.
69. Sartori D, Aronson JK, Erlanson N, Norén GN, Onakpoya IJ. A Comparison of Signals of Designated Medical Events and Non-designated Medical Events: Results from a Scoping Review. *Drug Saf.* 2024;47:475–85. <http://dx.doi.org/10.1007/s40264-024-01403-x>.
70. Vogel U, van Stekelenborg J, Dreyfus B, Garg A, Habib M, Hosain R, et al. Investigating Overlap in Signals from EVDAS, FAERS, and VigiBase®. *Drug Saf.* 2020;43:351–62. <http://dx.doi.org/10.1007/s40264-019-00899-y>.
71. Lavertu A, Vora B, Giacomini KM, Altman R, Rensi S. A New Era in Pharmacovigilance: Toward Real-World Data and Digital Monitoring. *Clin Pharmacol Ther.* 2021;109:1197–1202. <http://dx.doi.org/10.1002/cpt.2172>.
72. Banda JM. Fully connecting the Observational Health Data Science and Informatics (OHDSI) initiative with the world of linked open data. *Genomics Inform.* 2019;17(2):e13. <http://dx.doi.org/10.5808/GI.2019.17.2.e13>.
73. Piazza G, Hurwitz S, Galvin CE, Harrigan L, Baklla S, Hohlfelder B, et al. Alert-based computerized decision support for high-risk hospitalized patients with atrial fibrillation not prescribed anticoagulation: a randomized, controlled trial (AF-ALERT). *Eur Heart J.* 2019;41:1086–96. <http://dx.doi.org/10.1093/eurheartj/ehz385>.
74. Capobussi M, Banzi R, Moja L, Bonovas S, González-Lorenzo M, Liberati EG, et al. [Computerized decision support systems: EBM at the bedside]. *Recenti Prog Med.* 2016;107:589–91. <http://dx.doi.org/10.1701/2484.25970>.
75. Sallevelt BTGM, Huibers CJA, Heij JMJO, Egberts TCG, van Puijenbroek EP, Shen Z, et al. Frequency and Acceptance of Clinical Decision Support System-Generated STOPP/START Signals for Hospitalised Older Patients with Polypharmacy and Multimorbidity. *Drugs Aging.* 2021;39:59–73. <http://dx.doi.org/10.1007/s40266-021-00904-z>.

76. O'Mahony D. STOPP/START criteria for potentially inappropriate medications/potential prescribing omissions in older people: origin and progress. *Expert Rev Clin Pharmacol*. 2019;13:15–22, doi.org/10.1080/17512433.2020.1697676
77. Lyu S-Q, Yang Y-M, Zhu J, Wang J, Wu S, Zhang H, et al. The efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy compared with conventional antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. *Platelets*. 2020;31:931–40. <http://dx.doi.org/10.1080/09537104.2020.1780205>.
78. Biswas M, Murad MA, Ershadian M, Kali, Sukasem C. Risk of major adverse cardiovascular events in CYP2C19LoF genotype guided clopidogrel against alternative antiplatelets for CAD patients undergoing PCI: Meta-analysis. *Clin Transl Sci*. 2025;18:e70080. <http://dx.doi.org/10.1111/cts.70080>.
79. Subakumar K, Franklin BD, Garfield S. Analysis of the third WHO Global Safety Challenge “Medication Without Harm” patient-facing materials: exploratory descriptive study. *Eur J Hosp Pharm*. 2020;28:e100–e104. <http://dx.doi.org/10.1136/ejhpharm-2020-002434>.
80. Panchal J, Menat U, Desai C, Shah A. An evaluation of trigger tool method for adverse drug reaction monitoring at a tertiary care teaching hospital. *Perspect Clin Res*. 2021;12:33–38. http://dx.doi.org/10.4103/picr.picr_30_19.
81. Samal L, Khasnabish S, Foskett C, Zigmont K, Faxvaag A, Chang F, et al. Comparison of a Voluntary Safety Reporting System to a Global Trigger Tool for Identifying Adverse Events in an Oncology Population. *J Patient Saf*. 2022;18:611–16. <http://dx.doi.org/10.1097/pts.0000000000001050>.
82. Smith SN, Lanham MSM, Seagull FJ, Fabbri M, Dorsch MP, Jennings K, et al. System-Wide, Electronic Health Record–Based Medication Alerts for Appropriate Prescribing of Direct Oral Anticoagulants: Pilot Randomized Controlled Trial. *JMIR Form Res*. 2024;8:e64674. <http://dx.doi.org/10.2196/64674>.
83. Niemantsverdriet MSA, Tiel Groenestege WM, Khairoun M, Hoefer IE, van Solinge WW, Bellomo D, et al. Design, validation and implementation of an automated e-alert for acute kidney injury: 6-month pilot study shows increased awareness. *BMC Nephrol*. 2023;24:222. <http://dx.doi.org/10.1186/s12882-023-03265-4>.
84. Fukushima A, Iessa N, Balakrishnan MR, Pal SN. Smartphone-based mobile applications for adverse drug reactions reporting: global status and country experience.

- BMC Med Inform Decis Mak. 2022;22:51. <http://dx.doi.org/10.1186/s12911-022-01832-7>.
85. Seaneke SK, Darko DM, Nkansah E, Asamoah-Amoakohene A, Ashie A, Ewudzie JS, et al. First results from the lessons learnt from the deployment of the Med Safety App for reporting adverse drug reactions in Ghana. *Digit Health*. 2023;9. <http://dx.doi.org/10.1177/20552076231211276>.
 86. Kiguba R, Zakumumpa H, Ndagije HB, Mwebaza N, Ssenyonga R, Tregunno P, et al. Facilitators and Barriers to Uptake of the Med Safety Mobile App for Adverse Drug Reaction Reporting by Health Workers in Uganda: A Qualitative Study. *Drug Saf*. 2023;46:565–74. <http://dx.doi.org/10.1007/s40264-023-01303-6>.
 87. Alam R, Aguirre A, Stultz CM. Detecting QT prolongation from a single-lead ECG with deep learning. *PLoS Digit Health*. 2024;3:e0000539. <http://dx.doi.org/10.1371/journal.pdig.0000539>.
 88. Castelletti S, Dagradi F, Goulene K, Danza AI, Baldi E, Stramba-Badiale M, et al. A wearable remote monitoring system for the identification of subjects with a prolonged QT interval or at risk for drug-induced long QT syndrome. *Int J Cardiol*. 2018;266:89–94. <http://dx.doi.org/10.1016/j.ijcard.2018.03.097>.
 89. Bekkink MO, Koeneman M, de Galan BE, Bredie SJ. Early Detection Of Hypoglycemia In Type 1 Diabetes Using A Wearable Device Measuring Heart Rate Variability. *Endocrine Society*. 2018. Available from: <https://www.abstractsonline.com/pp8/#!/4482/presentation/7661>. [access 02.08.2025].
 90. Lehmann V, Föll S, Maritsch M, van Weenen E, Kraus M, Lagger S, et al. Noninvasive Hypoglycemia Detection in People With Diabetes Using Smartwatch Data. *Diabetes Care*. 2023;46:993–97. <http://dx.doi.org/10.2337/dc22-2290>.
 91. Cukic M, Annaheim S, Bahrami F, Defraeye T, Nys KD, Jörger M. Is personal physiology-based rapid prediction digital twin for minimal effective fentanyl dose better than standard practice: a pilot study protocol. *BMJ Open*. 2024;14:e085296. <http://dx.doi.org/10.1136/bmjopen-2024-085296>.
 92. Mena S, Moullin JC, Schneider M, Niquille A. Implementation of interprofessional quality circles on deprescribing in Swiss nursing homes: an observational study. *BMC Geriatr*. 2023;23:188. <http://dx.doi.org/10.1186/s12877-023-04335-w>.